Effectiveness and safety of echinocandins combination therapy with the standard of care compared to the standard of care monotherapy for the treatment of invasive aspergillosis infection: a meta-analysis
Frontiers in Pharmacology · 19.12.2024 · 15
DOI: 10.3389/fphar.2024.1500529 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 19.12.2024. Verfasst von Yazed Saleh Alsowaida und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, College of Pharmacy, University of Hail, Hail, Saudi Arabia. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
This meta-analysis aims to evaluate the effectiveness and safety of combining echinocandins with standard of care (SOC) antifungal drugs for treating invasive aspergillosis infection (IAI).
Method
We searched PubMed, Embase, and Cochrane Library from their inception to 25 July 2024. Our outcomes included clinical cure, mortality, and adverse drug reactions (ADRs). We compared echinocandins in combination with SOC antifungal agents against SOC monotherapy therapy. We used the random-effects model for the meta-analysis, and our estimated effects were reported as odds ratios (ORs) with 95% confidence intervals (CI).
Results
Ten studies were included in our meta-analysis comprising 1100 patients: 415 were in the echinocandin combination groups, and 685 were in the SOC groups. The clinical cure rate (OR 1.35, 95% CI: 0.75–2.42, p = 0.27), mortality (OR 0.90, 95% CI: 0.50–1.63, p = 0.73), and ADRs rate (OR 0.95, 95% CI: 0.49–1.82, p = 0.87) were not statistically different in echinocandins combination with SOC compared to SOC monotherapy. Notably, there is a signal for a better clinical cure rate in echinocandins in combination with SOC.
Conclusion
Our meta-analysis found no differences in clinical cure and mortality rate when using combination therapy of echinocandin antifungal agents with the SOC compared to SOC monotherapy. However, there is a signal for better outcomes with the echinocandins combination group. The ADRs in the echinocandins combination group were not worse than SOC monotherapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, College of Pharmacy, University of Hail, Hail, Saudi Arabia.
- Department of Health Informatics, College of Public Health, University of Hail, Hail, Saudi Arabia.
- Department of Pharmacy Practice, Pharmacy College, King Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, Pharmaceutical Care Department, King Abdulaziz Medical City, Riyadh,…
- Department of Pharmaceutics, College of Pharmacy, University of Hail, Hail, Saudi Arabia.
- Department of Internal Medicine and Adult Critical Care, College of Medicine, University of Ha'il, Hail, Saudi Arabia.
- Department of Pharmacy Practice, College of Clinical Pharmacy, King Faisal University, Al-Ahsa, Saudi Arabia.
Zitieren
APA
Alsowaida, Y. S., Alshoumr, B., Alowais, S. A., Bin Saleh, K., Alshammari, A., Alshurtan, K., & Wali, H. A. (2024). Effectiveness and safety of echinocandins combination therapy with the standard of care compared to the standard of care monotherapy for the treatment of invasive aspergillosis infection: a meta-analysis. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1500529
Vancouver
Alsowaida YS, Alshoumr B, Alowais SA, Bin Saleh K, Alshammari A, Alshurtan K, et al. Effectiveness and safety of echinocandins combination therapy with the standard of care compared to the standard of care monotherapy for the treatment of invasive aspergillosis infection: a meta-analysis. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1500529
BibTeX
@article{Alsowaida2024,
author = {Alsowaida, Yazed Saleh and Alshoumr, Bader and Alowais, Shuroug A and Bin Saleh, Khalid and Alshammari, Alia and Alshurtan, Kareemah and Wali, Haytham A},
title = {Effectiveness and safety of echinocandins combination therapy with the standard of care compared to the standard of care monotherapy for the treatment of invasive aspergillosis infection: a meta-analysis},
journal = {Frontiers in Pharmacology},
year = {2024},
volume = {15},
doi = {10.3389/fphar.2024.1500529}
}
EUVIMED